Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
نویسندگان
چکیده
Peptichemio (PTC), a mixture of six oligopeptides all containing m-L-sarcolysin, has previously shown impressive results in clinical trials. The tripeptide P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester) has been suggested as the main contributor to PTC activity. In contrast to its analogue melphalan, m-L-sarcolysin never reached clinical use. To allow a direct comparison, the corresponding melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester) was synthesized and its activity was compared with that of P2; the activities of melphalan and m-L-sarcolysin were studied in parallel. Cytotoxic activity in human tumor cell lines and some fresh human tumor specimens were analyzed as well as effects on cellular metabolism, macromolecular synthesis, and preliminary evaluation of the cell death characteristics. The results show that melphalan and m-L-sarcolysin display similar activity in these systems and that the tripeptides were more active than their parent monomers. Surprisingly however, the melphalan containing tripeptide J3 demonstrated a significantly more rapid and stronger activity than the m-L-sarcolysin analogue P2. Finally, the in vivo toxicity and activity of melphalan and J3 were investigated in mice bearing human leukemia cells in s.c. fibers. The in vitro results seem translatable into the in vivo situation, demonstrating better antileukemic effect of J3 but similar side effects as melphalan.
منابع مشابه
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Neuroblastoma is the most common extracranial solid tumor of childhood. The activity of J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester), an enzymatically activated melphalan prodrug, was evaluated in neuroblastoma models in vitro and in vivo. Seven neuroblastoma cell lines with various levels of drug resistance were screened for cytotoxicity of J1 alone or in combination with standard cy...
متن کاملSelective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide.
ID50 and ID90 values for L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester HCl (MF13), were determined in four murine (leukemia, lymphoma, melanoma, and lung) and eight human cancer cell lines (two leukemia, prostate, kidney, colon, two melanoma, and breast). Cytotoxic activity was 2-5 times higher than that of sarcolysin [(L-3-[bis(2-chloroethyl)amino]-L-phenylalanine] ...
متن کاملThe effects of DL-p-fluorophenylalanine and L-3-nitrotyrosine on the growth and biochemistry of the Taper liver tumor.
Two amino acid analogs, DL-p-fluorophenylalanine and L-3-nitrotyrosine, retarded the growth of Taper liver tumor in mice and increased mouse survival time. Both of the analogs were taken into the tumor cells in vitro and in vivo, and DL-p-fluorophenylalanine inhibited the uptake of L-phenylalanine in vitro. tRNA in the "pH 5 fraction" from tumor cells could be acylated with DL-p-fluorophenylala...
متن کاملDiet and Cholesterolemia. Vii. Effects of Methionine, Ethionine, and P-fluorophenylalanine.
متن کامل
The Effects of DL-/?-FluorophenylaIanine and L-3-Nitrotyrosine on the Growth and Biochemistry of the Taper Liver Tumor1
Two amino acid analogs, DL-p-fluorophenylalanine and L-3-nitrotyrosine, retarded the growth of Taper liver tumor in mice and increased mouse survival time. Both of the analogs were taken into the tumor cells in vitro and in vivo, and DL-p-fluorophenylalanine inhibited the uptake of L-phenylalanine in vitro. tRNA in the "pH 5 fraction" from tumor cells could be acylated with DL-p-fluorophenylala...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Molecular cancer therapeutics
دوره 2 12 شماره
صفحات -
تاریخ انتشار 2003